+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Treatment of severe chronic ocular graft-versus-host disease using 100% autologous serum eye drops from a sealed manufacturing system: a retrospective cohort study



Treatment of severe chronic ocular graft-versus-host disease using 100% autologous serum eye drops from a sealed manufacturing system: a retrospective cohort study



British Journal of Ophthalmology 101(3): 322-326



To analyse patients with chronic ocular graft-versus-host disease (GvHD) under treatment with 100% autologous serum eye drops from a sealed manufacturing system. 17 patients with chronic ocular GvHD received 100% autologous serum eye drops from single use vials manufactured in a sealed system. Retrospective analysis included visual acuity, corneal staining, frequency of artificial tears, ocular symptoms by means of a questionnaire and information on subjective side effects and cost compensation. Data of prior to autologous serum eye drops therapy and at a 6-month follow-up were obtained. They demonstrated a significant increase in visual acuity (logMAR oculus dexter/right eye (OD) 0.5±0.32 to 0.4±0.3; oculus sinister/left eye (OS) 0.6±0.35 to 0.3±0.35; p=0.177/0.003) and significant improvement in corneal staining (Oxford grading scheme: OD from 3±1.03 to 2±1.43, OS from 4±1.0 to 2±1.09, p=0.004/0.001) and ocular symptoms (ocular surface disease index: 88±20.59 to 63±22.77; p=0.02). Frequency of artificial tears was reduced and no side effects were reported. Patient satisfaction was 100%, and cost compensation by health insurance reached 80%. 100% autologous serum eye drops using a sealed manufacturing system were efficient in improving the ocular surface, patient symptoms and visual acuity without side effects. It seems to be safe to use 100% autologous serum despite earlier suspicions regarding immune complex accumulations and exacerbation of ocular surface inflammation. The potential effects of serum levels of systemic immunosuppressives through readministration onto the ocular surface need to be elucidated.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 059169189

Download citation: RISBibTeXText

PMID: 27267447

DOI: 10.1136/bjophthalmol-2015-307666


Related references

Autologous serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease. Bone Marrow Transplantation 31(7): 579-583, 2003

Autologous serum eye drops for severe dry eye syndrome in a patient with chronic graft-versus-host disease: a case report. International Journal of Pharmaceutical Compounding 18(5): 370-377, 2014

Allogeneic serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease. Cornea 26(7): 861-863, 2007

Cytokine profile of autologous platelet-derived eye drops in patients with ocular chronic graft-versus-host disease. Vox Sanguinis 110(2): 189-192, 2016

Semifluorinated Alkane Eye Drops in Chronic Ocular Graft-versus-Host Disease: A Prospective, Multicenter, Noninterventional Study. Ophthalmic Research 2019: 1-9, 2019

Allogeneic serum eye drops for the treatment of dry eye patients with chronic graft-versus-host disease. Journal of Ocular Pharmacology and Therapeutics 28(5): 479-483, 2012

Methotrexate treatment in severe chronic ocular graft versus host disease (GvHD). Klinische Monatsblatter für Augenheilkunde 230(4): 344-345, 2013

A Single-Center Pilot Prospective Study of Topical Application of Platelet-Derived Eye Drops for Patients with Ocular Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation 22(9): 1664-1670, 2016

Dry eye disease in chronic graft-versus-host disease: results from a Spanish retrospective cohort study. Transplantation Proceedings 43(5): 1934-1938, 2011

The effects of autologous serum eye drops in the treatment of ocular surface diseases a retrospective study. 2012

A retrospective crossover study of autologous and allogeneic serum eye drops for the management of ocular surface disease. Transfusion Medicine 29(1): 69-71, 2019

Single-Center Retrospective Study on Meibomian Gland Loss in Patients With Ocular Chronic Graft-Versus-Host Disease. Eye and Contact Lens 44(Suppl. 2): S169, 2018

Long-Term Topical Diquafosol Tetrasodium Treatment of Dry Eye Disease Caused by Chronic Graft-Versus-Host Disease: A Retrospective Study. Eye and Contact Lens 44(Suppl. 2): S215, 2018

Risk-factor analysis for predicting progressive- or quiescent-type chronic graft-versus-host disease in a patient cohort with a history of acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplantation 37(7): 699-708, 2006

Clinical significance of IgE in a large cohort of patients with moderate or severe chronic graft-versus-host disease. American Journal of Hematology 92(8): E162, 2017